Authority layer
Every claim on TanPrevent.org, sourced. Effect size, journal, PubMed link, and where a study has a real limitation, it's stated here rather than left out.
Practical choices
You do not need to tan. If you want a tanned appearance, sunless color avoids the UV exposure from sunbathing or tanning beds. It does not make every product or application method risk-free.
Dihydroxyacetone (DHA) colors the skin’s surface. FDA permits it for external skin application; keep it away from the eye area, lips and mucous membranes. A lotion or cream makes these areas and inhalation easier to avoid.
Sprays add inhalation and accidental eye or mouth exposure concerns. FDA has not approved DHA for all-over spray-booth use. Ask how the facility protects the entire eye area, lips and mucous membranes and prevents inhalation or ingestion. If those protections are unavailable, choose a non-spray option.
Tinted cosmetics provide temporary color without UV tanning. Check ingredients for known sensitivities. FDA has received reports of rashes and, particularly with spray tanning, coughing, dizziness and fainting; the causes are uncertain.
Color is not sun protection. Continue using broad-spectrum, water-resistant SPF 30 or higher sunscreen. Follow its label and reapply as directed; sunless color does not replace it.
Classification
Classified carcinogenic to humans — the same evidence category as tobacco smoking and asbestos. A classification of the strength of evidence, not an effect estimate; it says nothing about how much exposure is "safe."
First use before age 35: RR 1.75 (95% CI 1.35–2.26).
Melanoma risk — meta-analyses and cohorts
59% higher relative risk of melanoma when indoor tanning begins before age 35. RR 1.59 (95% CI 1.36–1.85).
The original paper printed 1.87; 1.59 is the figure after the published correction.
Adjusted odds of melanoma 2.85× in a retrospective matched analysis of roughly 6,000 people (melanoma in 5.1% of indoor tanners vs. 2.1% of matched controls). Single-cell sequencing of 182 melanocytes found indoor tanners carried close to twice the mutation burden of controls, including at habitually sun-protected sites.
Single-institution retrospective analysis, not a pooled or prospective estimate; open to detection bias since tanners in a dermatology system are screened more. Pedram Gerami is an author here and a member of the Working Group.
Adjusted RR 1.32 (95% CI 1.08–1.63) for melanoma in the highest tertile of cumulative sessions, in a cohort of 141,045 Norwegian women. Initiation before age 30: adj. RR 1.31 (95% CI 1.07–1.59).
Women only, one country — the most conservative estimate here, least vulnerable to recall bias.
76% of melanomas diagnosed in sunbed users aged 18–29 were attributable to sunbed use. OR 6.57 (95% CI 1.41–30.49) for diagnosis at 18–29; OR 2.01 (1.22–3.31) above ten lifetime sessions.
Wide confidence intervals, small strata.
Melanoma RR 1.27 (95% CI 1.16–1.39); early-onset melanoma RR 1.75 (1.14–2.69).
Ever use OR 1.16 (95% CI 1.05–1.28); more than ten sessions OR 1.34 (1.05–1.71).
Ever tanned, adjusted for sun exposure: OR 1.74 (95% CI 1.42–2.14).
Women aged 30–39: adjusted OR 2.3 (95% CI 1.4–3.6).
Solarium use more than monthly at ages 30–39: RR 1.49 (95% CI 1.11–2.00).
Those who burned in the device: OR 8.97 (95% CI 2.10–38.6).
Indoor tanning is associated with developing more than one independent primary melanoma — consistent with damage spread across a wide field of skin rather than a single site.
A two-page research letter; weigh it accordingly.
Non-melanoma skin cancer & population burden
SCC OR 1.67 (95% CI 1.29–2.17); BCC OR 1.29 (95% CI 1.08–1.53) with ever use of indoor tanning.
~400,000 US skin cancer cases per year modelled as attributable to indoor tanning — roughly 245,000 basal cell, 168,000 squamous cell, ~6,200 melanoma.
A modelled attributable estimate, not a case count.
HR 1.15 (95% CI 1.11–1.19) per four additional sessions per year.
Mechanism
Skin beta-endorphin mediates opioid-receptor-dependent analgesia after chronic UV exposure, with naloxone-precipitated withdrawal on blockade — a pharmacological dependence, not a figure of speech.
The tanning response runs downstream of p53 activation by DNA damage — a tan is the record of injury, not a defense against it.
Policy & regulation
2026 · Letter · Risk communication
The authors discuss gaps in how tanning-bed risks are communicated during consent and call for clearer warnings, checks of understanding, and education alongside behavioral and regulatory approaches.
What this evidence can tell us: This is a letter presenting an argument and recommendations, not an intervention trial. It does not demonstrate that a revised consent process reduces tanning or skin cancer. The cosmetic-tanning policy discussion does not concern or restrict medically supervised phototherapy.
Age-restriction laws: 47% lower prevalence in female high school students. Parental-permission laws alone: no association.
Secret-shopper study of 427 salons: 37.2% noncompliance with youth-access law.
Full ban modelled across North America: 240,000 melanomas averted, 423,000 life-years gained.
A modelled projection, not an observed outcome.
Adolescent past-year prevalence fell from 22.0% (95% CI 17.2–26.8) to 6.5% (3.3–10.6) following the classification and subsequent policy attention.
Frames indoor tanning as a behavioral and regulatory problem, not only a dermatological one.
The paper that first framed indoor tanning as a youth-access problem.
Assembled by systematic search and verified record by record. Where a confidence interval is not shown, the source reports none. Nothing here is individual medical advice.